Importance of fractional exhaled nitric oxide in the differentiation of asthma–COPD overlap syndrome, asthma, and COPD
Open Access
- 1 September 2016
- journal article
- research article
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 11 (1) , 2385-2390
Abstract
Background: Fractional exhaled nitric oxide (FeNO) is an easy, sensitive, reproducible, and noninvasive marker of eosinophilic airway inflammation. Accordingly, FeNO is extensively used to diagnose and manage asthma. Patients with COPD who share some of the features of asthma have a condition called asthma–COPD overlap syndrome (ACOS). The feasibility of using FeNO to differentiate ACOS patients from asthma and COPD patients remains unclear. Methods: From February 2013 to May 2016, patients suspected with asthma and COPD through physician’s opinion were subjected to FeNO measurement, pulmonary function test (PFT), and bronchial hyperresponsiveness or bronchodilator test. Patients were divided into asthma alone group, COPD alone group, and ACOS group according to a clinical history, PFT values, and bronchial hyperresponsiveness or bronchodilator test. Receiver operating characteristic (ROC) curves were obtained to elucidate the clinical functions of FeNO in diagnosing ACOS. The optimal operating point was also determined. Results: A total of 689 patients were enrolled in this study: 500 had asthma, 132 had COPD, and 57 had ACOS. The FeNO value in patients with ACOS was 27 (21.5) parts per billion (ppb; median [interquartile range]), which was significantly higher than that in the COPD group (18 [11] ppb). The area under the ROC curve was estimated to be 0.783 for FeNO. Results also revealed an optimal cutoff value of >22.5 ppb FeNO for differentiating ACOS from COPD patients (sensitivity 70%, specificity 75%). Conclusion: FeNO measurement is an easy, noninvasive, and sensitive method for differentiating ACOS from COPD. This technique is a new perspective for the management of COPD patients.Keywords
This publication has 20 references indexed in Scilit:
- Asthma-COPD Overlap Syndrome (ACOS): Single disease entity or not? Could exhaled nitric oxide be a useful biomarker for the differentiation of ACOS, asthma and COPD?Medical Hypotheses, 2016
- The Asthma–COPD Overlap SyndromeNew England Journal of Medicine, 2015
- External validation of blood eosinophils, FENOand serum periostin as surrogates for sputum eosinophils in asthmaThorax, 2014
- Characterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels: a pilot studyInternational Journal of Chronic Obstructive Pulmonary Disease, 2014
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEuropean Respiratory Journal, 2013
- High hospital burden in overlap syndrome of asthma and COPDThe Clinical Respiratory Journal, 2013
- The overlap syndrome of asthma and COPD: what are its features and how important is it?Thorax, 2009
- Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in mild to moderately severe asthmaThorax, 2000
- Exhaled nitric oxide; relationship to clinicophysiological markers of asthma severityRespiratory Medicine, 1998
- Acute and Chronic Effects of Cigarette Smoking on Exhaled Nitric OxideAmerican Journal of Respiratory and Critical Care Medicine, 1995